BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.43 -0.81%
EPS Growth %: +1,033.3%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: +1,033.3%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.96, $0.61 better than the analyst estimate of $0.35. Revenue for the quarter came in at $712 million versus the consensus estimate of $662.05 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $3.10-$3.25, versus the consensus of $2.87. BioMarin Pharma sees FY2024 revenue of $2.75-2.82 billion, versus the consensus of $2.74 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel (INTC) PT Lowered to $92 at Mizuho
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
